Share Issue/Capital Change • Sep 8, 2025
Share Issue/Capital Change
Open in ViewerOpens in native device viewer

| Informazione Regolamentata n. 20343-10-2025 |
Data/Ora Inizio Diffusione 8 Settembre 2025 17:49:11 |
Euronext Growth Milan | ||
|---|---|---|---|---|
| Societa' | : | OTOFARMA | ||
| Identificativo Informazione Regolamentata |
: | 209751 | ||
| Utenza - referente | : | OTOFARMAESTN01 - Anna Incarnato Bartolomucci |
||
| Tipologia | : | 2.5 | ||
| Data/Ora Ricezione | : | 8 Settembre 2025 17:49:11 | ||
| Data/Ora Inizio Diffusione | : | 8 Settembre 2025 17:49:11 | ||
| Oggetto | : | OTOFARMA: announcement of change in share capital following full exercise of greenshoe option |
||
Testo del comunicato
Vedi allegato


Naples, 8 September 2025 – The Otofarma Group – with over 30 years of experience in the hearing care sector and a leading manufacturer of hearing aids distributed mainly through the pharmaceutical channel – announces the new composition of its share capital following the issue of 190,500 ordinary shares of the Company relating to the full exercise of the Greenshoe Option in the capital increase (see press release of 2 September 2025) by Alantra Capital Markets S.A.U., Italian Branch (hereinafter also "Alantra"), granted by shareholder Bartolomucci Holding S.r.l. during the placement of its ordinary shares on the Euronext Growth Milan ("EGM") market.
The new composition of Otofarma's share capital (fully subscribed and paid up) following the filing of the certificate of change in share capital with the competent Companies Register of Naples is shown below:
| Current Share Capital | Previous Share Capital | Change | |||||||
|---|---|---|---|---|---|---|---|---|---|
| Euro | No. Shares Nom. Value. | Euro | No. Shares Nom. Value. | Euro | No. Shares |
Nom. Value. |
|||
| Total, of which |
1,635,484.47 | 5,947,000 | shares with no par value |
1,583,095 | 5,756,500 | shares with no par value |
52,389 | 190,500 | shares with no par value |
| Ordinary shares |
1,635,484.47 | 5,947,000 | shares with no par value |
1,583,095 | 5,756,500 | shares with no par value |
52,389 | 190,500 | shares with no par value |
Pursuant to Article 26 of the Euronext Growth Milan Issuers' Regulations, the Company hereby announces the composition of its shareholding structure, updated to the latest results in its possession:
| Shareholder | Number of Shares | % of Share Capital | % of Voting Rights |
|---|---|---|---|
| Bartolomucci Holding S.r.l. | 4,000,000 | 67.26% | 67.26% |
| Axon Partners Group SA | 592.800 | 9.97% | 9.97% |
| Invitalia S.p.A. (via Fondo | 381,600 | 6.42% | 6.42% |
| Cresci al Sud) | |||
| Algebris Investments | 333.300 | 5.60% | 5.60% |
| Market | 639,300 | 10.75% | 10.75% |
| TOTAL | 5,947,000 | 100% | 100% |
The shareholder structure is also available in the Shareholders section of the Company's website (www.otofarmaspa.com), under Investor Relations.
***************************


The Company uses the EMARKET SDIR and STORAGE circuit, managed by Teleborsa, for the dissemination of Regulated Information. This system is authorized by CONSOB by resolutions No. 22517 and No. 22518 of November 23, 2022, pursuant to Article 113-ter, paragraph 4, letter a, of Legislative Decree No. 58/1998. For further information on the greenshoe option, please refer to the admission document available in the Investor Relations section of the website www.otofarmaspa.com.
Alphanumeric Code: OTO ISIN for Ordinary Shares: IT0005663361
***
Otofarma Group is a leader in the design, production, and distribution of customized hearing aids through pharmacies. Its reputation is built on technological innovation and continuous research, offering advanced audiological solutions at a guaranteed democratic price, with the goal of making hearing care more accessible and widespread.
Pioneering in telemedicine, Otofarma was the first company in Europe to introduce specialist teleaudiology services in pharmacies, today available under Otofarma brand in more 4,000 partner pharmacies, making access to diagnosis and personalized devices easier.
Founded by Gennaro Bartolomucci, now Chairman, and led by CEO Giovanna Incarnato Bartolomucci, the company holds six patents for its proprietary software and instruments. Its devices and services are distributed exclusively through partner pharmacies, ensuring a controlled, quality-focused business model.
Anna Incarnato Bartolomucci E-mail: [email protected] mob: +39 347 0506780
E-mail: [email protected] mob: +39 334 6267242
+39 02 624 999 1 Michele Bon – [email protected] – +39 338 693 3868 Francesca Brambilla – [email protected] – +39 338 627 2146
Have a question? We'll get back to you promptly.